Company news

Delcath Systems, Inc. news in 2024

Delcath Systems, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

December 29, 2024

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

December 1, 2024

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

November 7, 2024

Delcath Systems to Host Third Quarter 2024 Earnings Call

October 24, 2024

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

October 16, 2024

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

September 15, 2024

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

August 27, 2024

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

August 26, 2024

Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

August 25, 2024

Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress

August 19, 2024

Delcath Systems Reports Second Quarter 2024 Results and Business Highlights

August 4, 2024

Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™

August 4, 2024

Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath’s Board of Directors

May 27, 2024

Delcath Systems Reports First Quarter 2024 Results and Business Highlights

May 13, 2024

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2024

Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

March 25, 2024

Delcath Systems Closes $7 Million Private Placement

March 19, 2024

Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call

March 18, 2024

Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

March 17, 2024

Delcath Systems Announces $7 Million Private Placement

March 14, 2024

Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

February 21, 2024

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

January 30, 2024

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™

January 15, 2024

Calls in 2024

Decks in 2024